Literature DB >> 26352279

Inhibition of cell proliferation and metastasis of human hepatocellular carcinoma by miR-137 is regulated by CDC42.

Ming Gao1, Liying Liu2, Shenglei Li3, Xudong Zhang1, Zhiwei Chang1, Mingzhi Zhang1.   

Abstract

In the present study, we evaluated the mechanisms of CDC42 in association with the microRNA-137 (miR-137)-induced inhibition of human hepatocellular carcinoma (HCC). The gene expression levels of miR-137 were evaluated in HCC cell lines. Direct association of miR-137 with its downstream target, cell division control protein 42 (CDC42), was evaluated by dual-luciferase assay, western blot analysis and correlation analysis using clinical tumor samples. In the HCC HuH7 and MHCC97L cell lines, miR-137 was upregulated to inhibit cell proliferation and metastasis in vitro and tumor growth in vivo. CDC42 was overexpressed in the HuH7 and MHCC97L cells to evaluate its effect on the miR-137-mediated antitumor effects. Furthermore, possible crosstalk between CDC42 and another miR-137 target gene, AKT2, was evaluated by co-overexpressing CDC42 and AKT2 in the HuH7 and MHCC97L cells and examining their effects on miR-137-mediated HCC regulation. miR-137 was confirmed to be downregulated in the HCC cell lines. Dual‑luciferase assay showed that CDC42 was directly targeted by miR-137, and western blotting showed that CDC42 was downregulated by miR-137 upregulation in the HuH7 and MHCC97L cells. In human tumors, the expression levels of CDC42 and miR-137 were inversely correlated. The inhibitory effects of miR-137 on HCC proliferation, metastasis and in vivo tumor growth were all ameliorated by CDC42 overexpression. Furthermore, co-overexpression of AKT2 in addition to CDC42 additively reduced the inhibition of miR-137 on HCC proliferation and metastasis, suggesting two independent pathways of CDC42 and AKT2 in miR-137-mediated HCC regulation. Our study demonstrated that CDC42 independently regulated the antitumor effects of miR-137 in human HCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26352279     DOI: 10.3892/or.2015.4261

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  11 in total

1.  MicroRNA-137 represses FBI-1 to inhibit proliferation and in vitro invasion and migration of hepatocellular carcinoma cells.

Authors:  Min Zhu; Mingyang Li; Tao Wang; Enqiang Linghu; Benyan Wu
Journal:  Tumour Biol       Date:  2016-08-04

2.  miR-185 enhances the inhibition of proliferation and migration induced by ionizing radiation in melanoma.

Authors:  Jinpeng He; Ning Tian; Yanli Yang; Liangliang Jin; Xiu Feng; Junrui Hua; Sulan Lin; Bing Wang; He Li; Jufang Wang
Journal:  Oncol Lett       Date:  2017-02-08       Impact factor: 2.967

3.  Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network.

Authors:  Yilong Li; Yongwei Wang; Rui Kong; Dongbo Xue; Shangha Pan; Hua Chen; Bei Sun
Journal:  Oncotarget       Date:  2016-09-20

4.  Antagonism between the RNA-binding protein Musashi1 and miR-137 and its potential impact on neurogenesis and glioblastoma development.

Authors:  Mitzli X Velasco; Adam Kosti; Gabriela D A Guardia; Marcia C Santos; Allison Tegge; Mei Qiao; Bruna R S Correa; Greco Hernández; Erzsebet Kokovay; Pedro A F Galante; Luiz O F Penalva
Journal:  RNA       Date:  2019-04-19       Impact factor: 4.942

5.  Bioinformatic analysis and in vitro validation of a five-microRNA signature as a prognostic biomarker of hepatocellular carcinoma.

Authors:  Wang Li; Xiangshuo Kong; Tao Huang; Lujun Shen; Peihong Wu; Qi-Feng Chen
Journal:  Ann Transl Med       Date:  2020-11

6.  Upregulation of miR-137 Expression Suppresses Tumor Growth and Progression via Interacting with DNMT3a Through Inhibiting the PTEN/Akt Signaling in HCC.

Authors:  Jiachen Wang; Zhao Wang; Jiaxiang Yuan; Qun Wang; Xinsheng Shen
Journal:  Onco Targets Ther       Date:  2021-01-08       Impact factor: 4.147

7.  GAS5 rs2067079 and miR-137 rs1625579 functional SNPs and risk of chronic hepatitis B virus infection among Egyptian patients.

Authors:  Rania H Mahmoud; Enas Mamdouh Hefzy; Olfat G Shaker; Tarek I Ahmed; Noha K Abdelghaffar; Essam A Hassan; Amal A Ibrahim; Doaa Y Ali; Mohamed M Mohamed; Omayma O Abdelaleem
Journal:  Sci Rep       Date:  2021-10-08       Impact factor: 4.379

8.  HEY2, a target of miR-137, indicates poor outcomes and promotes cell proliferation and migration in hepatocellular carcinoma.

Authors:  Dan-Chun Wu; Mei-Fang Zhang; Shu-Guang Su; Heng-Ying Fang; Xue-Hua Wang; Dan He; Yuan-Yuan Xie; Xu-Hui Liu
Journal:  Oncotarget       Date:  2016-06-21

9.  Variants of MIR137HG Genes are Associated with Liver Cancer Risk in Chinese Li Population.

Authors:  Chaoying Wang; Xiaohong Zhuang; Junnv Xu; Zhisheng Dai; Weixiong Wu; Chengsheng Zhang; Shu Lin; Sehong Chen; Haifeng Lin; Wenjun Tang
Journal:  Onco Targets Ther       Date:  2020-02-28       Impact factor: 4.147

10.  MicroRNA‑137 has a suppressive role in liver cancer via targeting EZH2.

Authors:  Shichang Cui; Yanlei Sun; Yang Liu; Chengbiao Liu; Jinbao Wang; Guang Hao; Qidong Sun
Journal:  Mol Med Rep       Date:  2017-10-19       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.